Table 1.
Clinical characteristics of CHB patients and HCs in the study
| Group | IT | IA | IC | HC |
|---|---|---|---|---|
| No. of Cases | 13 | 17 | 21 | 21 |
| Gender (M/F) | 10/3 | 11/6 | 17/4 | 8/13 |
| Age (years) | 31(27–33) | 28(26–34) | 36(30–39) | 27(25–34) |
| HBsAg | + | + | + | − |
| HBeAg | + | + | − | − |
| ALT (U/L) | 32.9 | 104 | 27.1 | 18.9 |
| (23.95–45.5) | (73.5–150) | (19.7–37.1) | (9.475–33.8) | |
| HBV DNA | 7.528 | 6.812 | ND | ND |
| (log10 IU/ml) | (7.33–7.826) | (5.318–7.61) |
HC healthy controls, IA immune reactive HBeAg-positive phase, IC Inactive HBV carrier state, IT Immune tolerant phase, ND not detectable, ALT alanine transaminase. Data are shown as median and range